Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
News|Articles|January 2, 2004
- Pharmaceutical Technology-01-02-2004
- Volume 28
- Issue 1
New Supply-Chain Dynamics
Author(s)Jim Miller
As manufacturers move to manufacture to demand rather than to forecast, the traditional wholesaling business model is being transformed.
Advertisement
Articles in this issue
almost 23 years ago
Coprocessed Excipients for Solid Dosage Formsalmost 23 years ago
Manufacturing Execution Systemsalmost 23 years ago
State-of-the-Art Packaging Machinesalmost 23 years ago
January 2004almost 23 years ago
Medicare Bill Contains Significant Changes for Drug Manufacturersalmost 23 years ago
The Bioterrorism Actalmost 23 years ago
In the Spotlight--February 2004almost 23 years ago
January 2004Advertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
Advertisement
Advertisement